2025 Volume 28 Issue 3 Pages 478-485
Introduction: The combined use of vancomycin and piperacillin/tazobactam (PIPC/TAZ) (VPT) increases the risk of acute kidney injury (AKI). To the best of our knowledge, no previous study has compared the incidence of AKI in critically ill emergency patients treated with teicoplanin and PIPC/TAZ (TPT). This study aimed to assess the incidence of AKI in critically ill emergency patients who received VPT or TPT.
Methods: Patients treated with VPT or TPT at a trauma and critical care center of Osaka Metropolitan University Hospital between April 2012 and December 2024 were included. We analyzed the patient characteristics, AKI incidence, antimicrobial agent dosage, concomitant medications affecting renal function, and comorbidities in both groups.
Results: The VPT and TPT groups comprised 25 and 22 patients, respectively. There were no significant differences in the use of nephrotoxic agents or concomitant diseases between the two groups. AKI occurred in 36.0% and 9.1% of patients in the VPT and TPT groups, respectively, and the incidence was significantly lower in the TPT group (p=0.041).
Discussion: These findings suggest that TPT may be a safer alternative to VPT for minimizing the risk of AKI in critically ill emergency patients.
